Number of eligible patients: CDEC mentioned the uncertainty in the amount of individuals with moderately severe to extreme hemophilia B in Canada suitable for etranacogene dezaparvovec. Medical industry experts consulted by CADTH indicated that some clients who are categorised as getting mild or ave